273 related articles for article (PubMed ID: 15540174)
1. Assessing the feasibility of single lifetime PAP smear evaluation between 41-50 years of age as strategy for cervical cancer control in developing countries from our 32 years of experience of hospital-based routine cytological screening.
Misra JS; Gupta HP; Das V
Diagn Cytopathol; 2004 Dec; 31(6):376-9. PubMed ID: 15540174
[TBL] [Abstract][Full Text] [Related]
2. Results of longterm hospital based cytological screening in asymptomatic women.
Misra JS; Singh U
Diagn Cytopathol; 2006 Mar; 34(3):184-7. PubMed ID: 16470854
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer screening in a rural population of Zimbabwe.
Thistle PJ; Chirenje ZM
Cent Afr J Med; 1997 Sep; 43(9):246-51. PubMed ID: 9509642
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a hospital based cytology screening programme for reduction in life time risk of cervical cancer.
Agarwal SS; Murthy NS; Sharma S; Sharma KC; Das DK
Neoplasma; 1995; 42(2):93-6. PubMed ID: 7617084
[TBL] [Abstract][Full Text] [Related]
5. Single life time cytological screening in high risk women as an economical and feasible approach to control cervical cancer in developing countries like India.
Misra JS; Srivastava AN; Das V
Asian Pac J Cancer Prev; 2015; 16(3):859-62. PubMed ID: 25735373
[TBL] [Abstract][Full Text] [Related]
6. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population.
Syrjänen K; Hakama M; Saarikoski S; Väyrynen M; Yliskoski M; Syrjänen S; Kataja V; Castrén O
Sex Transm Dis; 1990; 17(1):15-9. PubMed ID: 2154865
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer screening program of Paraná: cost-effective model in a developing country.
Bleggi Torres LF; Werner B; Totsugui J; Collaço LM; Araújo SR; Huçulak M; Boza EJ; Fischer RM; De Laat L; Sobbania LC; Raggio A
Diagn Cytopathol; 2003 Jul; 29(1):49-54. PubMed ID: 12827718
[TBL] [Abstract][Full Text] [Related]
8. Cervical cancer in India--strategy for control.
Prabhakar AK
Indian J Cancer; 1992 Sep; 29(3):104-13. PubMed ID: 1292993
[TBL] [Abstract][Full Text] [Related]
9. Downstaging of cervical cancer.
Ananth R
J Indian Med Assoc; 2000 Feb; 98(2):41-4. PubMed ID: 11016148
[TBL] [Abstract][Full Text] [Related]
10. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
11. [Are analyses of cytological cervix smears from young women more harmful than beneficial?].
Skjeldestad FE; Hagen B; Hagmar B; Iversen OE; Juvkam KH; Steen R; Thoresen S; Hareide B
Tidsskr Nor Laegeforen; 2007 Jun; 127(13):1782-5. PubMed ID: 17599128
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of a hospital based cytology screening program.
Das DK; Murthy NS; Bhatnager P; Juneja A; Sharma S; Pant JN; Bhatt NC; Sharma KC; Luthra UK
Neoplasma; 1992; 39(6):381-4. PubMed ID: 1491729
[TBL] [Abstract][Full Text] [Related]
13. Cervical cancer control in developing countries: memorandum from a WHO meeting.
Bull World Health Organ; 1996; 74(4):345-51. PubMed ID: 8823955
[TBL] [Abstract][Full Text] [Related]
14. Organization of screening programs in developing countries with reference to screening for cancer of the uterine cervix in India.
Luthra UK; Rengachari R
IARC Sci Publ; 1986; (76):273-88. PubMed ID: 3570411
[TBL] [Abstract][Full Text] [Related]
15. Effective screening programmes for cervical cancer in low- and middle-income developing countries.
Sankaranarayanan R; Budukh AM; Rajkumar R
Bull World Health Organ; 2001; 79(10):954-62. PubMed ID: 11693978
[TBL] [Abstract][Full Text] [Related]
16. Review of screening and preventive strategies for cervical cancer in India.
Patro BK; Nongkynrih B
Indian J Public Health; 2007; 51(4):216-21. PubMed ID: 18232160
[TBL] [Abstract][Full Text] [Related]
17. [The role of the cytological screening, HPV-test and the colposcopy for early detection of the precancerous lesions of the uterine cervix].
Ivanov S
Akush Ginekol (Sofiia); 2007; 46(9):45-9. PubMed ID: 18646309
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of adding human papilloma virus testing to a managed care cervical cancer screening program.
Lonky NM; Hunter MI; Sadeghi M; Edwards G; Bajamundi K; Monk BJ
J Low Genit Tract Dis; 2007 Oct; 11(4):258-64. PubMed ID: 17917570
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening.
Bidus MA; Maxwell GL; Kulasingam S; Rose GS; Elkas JC; Chernofsky M; Myers ER
Obstet Gynecol; 2006 May; 107(5):997-1005. PubMed ID: 16648402
[TBL] [Abstract][Full Text] [Related]
20. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
